BURNABY, BRITISH COLUMBIA--(Marketwired - March 26, 2014) - LED Medical Diagnostics Inc. (TSX VENTURE:LMD)(OTCQX:LEDIF)(FRANKFURT:LME) ("LED Medical" or the "Company") announced today that it has appointed Dr. Jeffrey Brooks to the role of Vice President of Imaging for LED Dental Ltd. ("LED Dental"), a wholly-owned US subsidiary of LED Medical Diagnostics Inc.
Dr. Brooks is a board certified Oral and Maxillofacial Surgeon with 20 years of private practice experience. He has a special interest in 3D Imaging technology and holds multiple technology certifications. "I have had the pleasure of working with Jeff for many years during my tenure at Carestream, where he was Vice President of Clinical Affairs," states Dr. David Gane, CEO of LED Medical. "His passion and dedication are unsurpassed and I am delighted that he has chosen to bring his knowledge and expertise to the leadership team at LED Dental." Dr. Brooks will continue to maintain his positions as Associate Professor and 3D Imaging Director in the Department of Oral and Maxillofacial Surgery at University of Tennessee at Memphis.
LED Dental's VELscope® Vx Enhanced Oral Assessment System is currently the world's most frequently used adjunctive technology when screening for oral tissue anomalies, including early stage oral cancer and pre-cancer. Despite this accomplishment, management believes the company has only superficially tapped into its clinical and commercial potential.
In the last half of 2013, LED Dental initiated a change of leadership personnel in preparation for its next stage of evolution. "The addition of Jeff to our team marks another important milestone in our team building efforts. With his drive, energy, experience and knowledge, Jeff will play a key role in our corporate growth strategy and accelerate our efforts to introduce new diagnostic imaging products as we work to become a leading player in the dental industry," continues Dr. Gane.
About LED Medical Diagnostics Inc.
Founded in 2003 and headquartered in Burnaby, British Columbia, Canada, LED Medical Diagnostics Inc. is a leading developer of LED‐based visualization technologies for the medical industry. The Company is currently listed on the Toronto Stock Exchange (TSX‐V) under the symbol "LMD", the OTCQX under the symbol "LEDIF", as well as the Frankfurt Stock Exchange under the symbol "LME". For more information, visit www.ledmd.com.
Through its wholly‐owned subsidiary, LED Dental Inc., the company manufactures the VELscope® Vx Enhanced Oral Assessment System, the first system in the world to apply tissue fluorescence visualization technology to the oral cavity. VELscope® Vx devices are now used to conduct more screenings for oral cancer and other oral diseases than any other adjunctive device. To date, there have been more than 12,000 VELscope® Vx systems sold globally and they have been used to perform more than 25 million exams. For more information, call 604.434.4614 or visit www.leddental.com.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward Looking Statements
This press release contains statements which, to the extent that they are not recitations of historical fact, may constitute forward-looking information under applicable Canadian securities legislation that involve risks and uncertainties. Such forward-looking statements or information include statements regarding, but not limited to the Company's future distribution strategy and product offering, and the potential expansion of the Company's technology to other medical applications or markets, or the potential introduction of new technologies to the Company. Persons reading this press release are cautioned that such statements or information are only predictions, and that the Corporation's actual future results or performance may be materially different. Factors that could cause actual events or results to differ materially from those suggested by these forward-looking statements include, but are not limited to competition risks, distributor risks, product development risks such as regulatory, design, intellectual property and other factors described in the Corporation's reports filed on SEDAR including its Annual Information Form and financial report for the year ended December 31, 2012. These and other factors should be considered carefully and readers should not place undue reliance on such forward-looking information. All forward-looking statements made in this press release are qualified by this cautionary statement and there can be no assurance that actual results or developments anticipated by the Company will be realized. The Company disclaims any intention or obligation to update or revise forward-looking information, whether as a result of new information, future events or otherwise, except as required by law.